Connexon Creative - Mammary Cell News 1.27, November 19th, 2009

In this issue: Science News | Current Publications | Industry News | Policy News | Events

TOP STORIES

Cornell Researchers Identify a Weak Link in Cancer Cell Armor
Researchers have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53, a gene mutated in the majority of human cancers. [Cornell University College of Veterinary Medicine, Ithaca]

SPECIAL FEATURE

Video - MammoCult®: Optimized and defined medium for the culture of human mammospheres and tumorspheres

SCIENCE NEWS

New Combination Therapy Could Deliver a Powerful Punch to Breast Cancer
A powerful new breast cancer treatment could result from packaging one of the newer drugs that inhibits cancer's hallmark wild growth with another that blocks a primordial survival technique in which the cancer cell eats part of itself. [Medical College of Georgia Cancer Center, Augusta]

UMass Amherst Chemical Engineer Develops System to 'Detonate' Cancer-Killing TRAIL inside Tumors on Command
Experiments confirm that University of Massachusetts Amherst chemical engineer Neil Forbes' delivery and trigger system has for the first time successfully placed TRAIL, a cancer-fighting protein, directly into solid tumors and on cue, turned it on. [Pioneer Valley Life Sciences Institute, Baystate Medical Center, Springfield]

CURRENT PUBLICATIONS

LABORATORY RESEARCH

An Epigenetic Switch Involving NF-KappaB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation
Transient activation of Src oncoprotein can mediate an epigenetic switch from immortalized breast cells to a stably transformed line that forms self-renewing mammospheres that contain cancer stem cells. [Cell]

Dual Inactivation of Hus1 and p53 in the Mouse Mammary Gland Results in Accumulation of Damaged Cells and Impaired Tissue Regeneration
Results establish a requirement for Hus1 in the survival and proliferation of mammary epithelium and identify a role for p53 in mammary gland tissue regeneration and homeostasis. [PNAS]

Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling
Activation of both ER and erbB2/erbB3 signaling is requisite for estrogen-induced mitogenesis and erbB2/neu tyrosine kinase activation. [Mol Cancer Res]

p34SEI-1 Inhibits Doxorubicin-Induced Senescence Through a Pathway Mediated by Protein Kinase C-Delta and c-Jun-NH2-Kinase 1 Activation in Human Breast Cancer MCF7 Cells
p34SEI-1 inhibits senescence by inducing PKC-Delta ubiquitination and preventing PKC-Delta-dependent phosphorylation of JNK1. [Mol Cancer Res]

Repeated Treatment with Subtoxic Doses of TRAIL Induces Resistance to Apoptosis through its Death Receptors in MDA-MB-231 Breast Cancer Cells
Tumor cells could acquire resistance to TRAIL therapy especially when they are repeatedly exposed to low levels of the death ligand, highlighting the necessity of combination with therapies that target the resistance mechanisms. [Mol Cancer Res]

CLINICAL RESEARCH

Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Ixabepilone demonstrates antitumor activity and acceptable safety in patients with platinum- and taxane-resistant recurrent or persistent ovarian or primary peritoneal carcinoma. [J Clin Oncol]

INDUSTRY NEWS

bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients.

Genentech Submits Supplemental Applications to FDA for Avastin Combined With Commonly Used Chemotherapies for Women With Advanced Breast Cancer
Genentech, Inc. today announced that the company submitted two supplemental Biologics License Applications to the U.S. Food and Drug Administration for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer.

POLICY NEWS

Senate Dem Leader Bringing Out New Health Bill, 10-Year Plan would Cost $849 Billion, Add Coverage for 31 Million
The Senate's top Democrat on Wednesday prepared to unveil a new health care bill that aims to meet President Barack Obama's goal of expanding coverage without adding to the federal deficit.

EVENTS

32nd Annual CTRC - AACR San Antonio Breast Cancer Symposium
December 9-13, 2009
San Antonio, TX

Gordon Research Conference - Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

The 21st Meeting of the European Association for Cancer Research
June 26-29, 2010
Oslo, Norway

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Manager, Market Segment Regenerative Medicine (Sigma-Aldrich Corporation)

Technical Specialist (AABB)

R&D Scientist (STEMCELL Technologies)

Technical Support Representative - France (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Learn more about Mammary Cell News: Archives | Events | Update Profile | Contact Us

This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada